Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-059533
Filing Date
2025-04-29
Accepted
2025-04-29 06:05:38
Documents
19
Period of Report
2025-06-11

Document Format Files

Seq Description Document Type Size
1 DEF 14A krro-20250428.htm   iXBRL DEF 14A 1074695
2 GRAPHIC img84946324_0.jpg GRAPHIC 59164
3 GRAPHIC img84946324_1.jpg GRAPHIC 59164
4 GRAPHIC img84946324_2.jpg GRAPHIC 367770
5 GRAPHIC img84946324_3.jpg GRAPHIC 370044
6 GRAPHIC img84946324_4.jpg GRAPHIC 608700
7 GRAPHIC img84946324_5.jpg GRAPHIC 412380
  Complete submission text file 0000950170-25-059533.txt   6407412

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT krro-20250428.xsd EX-101.SCH 13704
21 EXTRACTED XBRL INSTANCE DOCUMENT krro-20250428_htm.xml XML 348411
Mailing Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141
Business Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141 617-468-1999
Korro Bio, Inc. (Filer) CIK: 0001703647 (see all company filings)

EIN.: 472324450 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39062 | Film No.: 25882476
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)